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 Abstract 
  Background:  Recent studies reported that cerebral microbleeds (CMBs), i.e. small areas of signal 
loss on T  2    *  -weighted gradient-echo (GE) imaging, could develop rapidly after acute ischemic 
stroke. We hypothesized that CMBs rapidly emerge after carotid artery stenting (CAS).   Objec-
tive:   We investigated the frequency of and predisposing factors for CMBs after CAS.   Methods:  
We retrospectively examined MRI before and after CAS in 88 consecutive patients (average age: 
71.7   8   7.2 years, average rates of carotid stenosis: 72.6   8   12.8%) who underwent CAS for ca-
rotid artery stenosis between March 1, 2009, and September 30, 2010. We defined new CMBs as 
signal losses that newly appeared on the follow-up GE. We examined the association of new 
CMBs with demographics, risk factors, and baseline MBs.  Results:  Among 88 patients, 18 (20.5%) 
had CMBs initially, and 7 (8.0%) developed new CMBs right after CAS. New CMBs appeared on 
the same side of CAS in all of the 7 patients. New CMBs appeared significantly more frequently 
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in the CMB-positive group than in the CMB-negative one (22% vs. 4%, p = 0.03) on the pre-CAS 
MRI. Multivariate analysis also revealed that the presence of CMBs before CAS was an indepen-
dent predictor of new development of CMBs after CAS (odds ratio: 8.09, 95% confidence inter-
val: 1.39–47.1).  Conclusion:  CMBs can develop rapidly after CAS, especially in patients with pre-
existing CMBs. Since the existence of CMBs prior to CAS suggests a latent vascular damage 
which is vulnerable to hemodynamic stress following CAS, particular attention should be paid 
to the prevention of intracerebral hemorrhage due to hyperperfusion after CAS. 
  Copyright © 2012 S. Karger AG, Basel 
 Introduction 
  Cerebral microbleeds (CMBs) are focal hemosiderin deposits adjacent to small vessels 
resulting from minimal blood leakage from small vessels that appear as signal loss lesions on 
T  2  *  -weighted gradient-echo (GE) magnetic resonance imaging (MRI). CMBs can be regard-
ed as a marker of microangiopathy   [1, 2]  . A recent review of the literature suggests that there 
is a strong association between CMBs identified on MRI and histopathological evidence of 
previous hemorrhage, most commonly in the form of hemosiderin-laden macrophages   [3] . 
Many studies suggested that CMBs could be associated with an increased risk of intracere-
bral hemorrhage (ICH) and cerebral amyloid angiopathy  [4–7]  and can develop rapidly after 
acute ischemic stroke   [8] .
  Cerebral hyperperfusion after carotid artery stenting (CAS) and carotid endarterectomy 
(CEA) is well known, and is defined as a marked increase in ipsilateral cerebral blood flow 
following surgical repair of carotid stenosis that results in a risk of ICH   [9–17]  . We hypoth-
esized that CMBs may develop rapidly after CAS. This study investigated the frequency and 
predisposing factors of new CMB formation after CAS.
  M e t h o d s  
 Patients 
  We retrospectively examined 88 consecutive patients who underwent CAS for carotid 
stenosis and MRI before and after CAS between March 1, 2009, and September 30, 2010, in 
Kokura Memorial Hospital. The preoperative degree of carotid stenosis was evaluated based 
on the North American Symptomatic Carotid Endarterectomy Trial (NASCET) criteria  [18] . 
Clinical presentation was classified as symptomatic or asymptomatic. Symptomatic carotid 
stenosis was defined as either a transient ischemic attack or a nondisabling stroke on the side 
ipsilateral to CAS within 6 months before CAS. This study was approved by our Institution-
al Review Board. We have obtained informed consent from the patients.
  Magnetic  Resonance  Imaging 
  MRI examinations were performed before and one day after CAS with a 1.5-T magnetic 
resonance system using a standard head coil. The gradient recalled echo (GRE) parameters 
were as follows: repetition time = 700 ms, echo time = 20 ms, flip angle = 25, matrix = 288 
  !  256, field of view = 220  !  220, slice thickness = 5 mm, and interslice gap = 2 mm. Patients 
with probable cerebral amyloid angiopathy according to the Boston criteria were excluded. 
The presence of CMBs on GRE MRI was independently evaluated by 2 neurologists (S.M, 
K.K) blind to the clinical details. CMBs were defined as focal areas of very low signal inten-
sity, with a diameter smaller than 10 mm. The number and location of CMBs were assessed. 
The location of CMBs were classified as (1) lobar: in the cortex, subcortex, and white matter 11
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of frontal, temporal, parietal, and occipital lobes; or (2) deep or infratentorial: in the caudate, 
putamen, globus pallidus, internal capsule, thalamus, brainstem, and cerebellum. Hypoin-
tense lesions within the subarachnoid space were regarded as pial blood vessels. Symmetric 
hypointense lesions in the area of the globus pallidus were regarded as calcification. We 
aligned the GRE slices of the pre- and post-CAS MRI to guarantee a precise comparison. 
When CMBs were identified on the post-CAS GRE, their prior absence was confirmed by 
re-examining the corresponding pre-CAS GRE.
    Technetium-99m Hexamethylpropyleneamine Oxime SPECT 
  Technetium-99m hexamethylpropyleneamine oxime (  99m  Tc-HMPAO) SPECT was per-
formed the next day after CAS. Patients received 15 mCi (555 MBq)   99m  Tc-HMPAO, and the 
first scan for cerebral blood flow imaging was started 5 min later (acquisition time: 20 min). 
The images were reconstructed in a 128   !   128 matrix with a section thickness of 5 mm on 
the transverse, sagittal, and coronal planes. An irregular, mirror-shaped region of interest 
was placed manually and bilaterally over the whole middle cerebral artery territory at the 
level of the parietal lobe, excluding the infarct, and the corresponding contralateral region. 
The asymmetry index (AI; affected side counts per pixel/contralateral side counts per pixel 
  !   100%) was calculated. In the present study, hyperperfusion after CAS was defined as an 
AI increase of   1  6.1% as described previously   [19] .
  Clinical  Assessments 
  The diagnosis of hypertension was based on either the use of antihypertensives or a sys-
tolic blood pressure   1  140 mm Hg and/or diastolic blood pressure   1  90 mm Hg during two 
separate measurements after the acute stroke period. The diagnosis of diabetes mellitus was 
based on the use of antidiabetic treatment or HbA1c   1  6.1%. Current smoking was assigned 
to persons who smoked during the 3 months preceding the last stroke event. Hyperlipidemia 
was determined when total cholesterol was   1  210 mg/dl or low-density lipoprotein choles-
terol was   1  130 mg/dl. Demographics including age, sex, and stroke risk factors were ob-
tained.
    Cerebral hyperperfusion syndrome (CHS) after CAS was diagnosed according to the 
following criteria: (1) severe headache, seizure, deterioration of consciousness level or the 
development of focal neurological signs such as motor weakness; (2) absence of any addi-
tional ischemic lesion on CT or MRI; (3) an increase in AI by   1 6.1%.
  P r o c e d u r a l   Te c h n i q u e s  
  All patients were pretreated with aspirin (100 mg/day) and clopidogrel (75 mg/day), or 
cilostazol (200 mg/day) for at least 3 days before the procedure. Eight patients also took war-
farin for complicating atrial fibrillation in addition to antiplatelet drugs. Carotid angio-
plasty and stent placement were performed by transfemoral catheterization under local an-
esthesia. The distal protection of a Percusurge Guard Wire System (Medtronic AVE, Santa 
Rosa, Calif., USA) or EZ filter System (Boston Scientific, Natick, Mass., USA) was used to 
cross and pre-dilate the stenosis. Pre-dilatation was performed with a controlled-compliant 
balloon dilation catheter to achieve a minimal lumen for passage of the stent-mounted cath-
eter. The balloon was inflated with 6–10 atm for 30 s. Next, a self-expanding stent was de-
ployed. The stent system used in this series consisted of a Precise (Johnson and Johnson, 
Miami Lakes, Fla., USA) in 55 cases, a Wallstent RP (Boston Scientific) in 29 cases, and a 
Driver (Medtronic Inc., Santa Rosa, Calif., USA) in 4 cases. Post-stenting dilatation was per-
formed with a controlled compliant balloon dilation catheter. The balloon size was selected 
according to the normal luminal diameter of each internal carotid artery just distal to the 
stenotic segment (diameter at full dilation was usually 4.0–5.0 mm). The balloon was in-12
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flated with 6–10 atm for 10–30 s. Intravenous heparin was administered during the proce-
dure, which was controlled to an activated clotting time (ACT) of around 300 s and not 
reversed at completion. A systolic blood pressure of   !  140 mm Hg was maintained for two 
days after the procedure. For patients at high risk of CHS, we strictly controlled blood pres-
sure to  ! 120 mm Hg for two days after CAS. Because the carotid sinus reflex usually lowered 
blood pressure after CAS, intravenous catecholamine was occasionally administered to 
maintain blood pressure.
  Statistical  Analysis 
  Student’s t test was used to analyze continuous data, and the     2   test was used for cate-
gorical data. Multiple logistic regression analysis was performed to estimate the independent 
predicting factors for the development of new CMBs after CAS. Variables with a p value  ! 0.1 
by univariate analysis, age, and risk factors were selected for entry into multiple regression 
analysis. A 2-tailed p value  ! 0.05 was considered a significant difference. SPSS for Windows 
(version 13.0, SPSS Inc., Chicago, Ill., USA) was used for all statistical analyses.
  R e s u l t s  
  A total of 100 patients underwent CAS for intracranial artery stenosis in our hospital 
during the study period, 12 patients did not undergo GRE MRI. Therefore, we analyzed 88 
patients (average age: 71.7   8   7.2 years, male: 86%, 40 symptomatic and 48 asymptomatic 
cases, average rates of carotid stenosis: 72.6   8   12.8%). Carotid stenosis was successfully 
treated in all patients. No patients had CHS. Demographics of the enrolled patients are shown 
in   table 1  . Eighteen patients (20.5%) had CMBs at baseline. The median number of baseline 
CMBs was 2 (range: 1–5). On the follow-up MRI, we observed 8 new CMBs ipsilateral to CAS 
in 7 patients (8.0%). The median number of new CMBs among these patients was 1 (range: 
1–2). There were no baseline CMBs in 3 patients who developed new CMBs. A representative 
case with new CMBs after CAS is shown in   figure 1  .
    By univariate analysis, the frequency of new CMB appearance was significantly higher 
in the initially CMB-positive group than the CMB-negative group (22% vs. 4%, p = 0.03). 
There was no significant association between the appearance of new CMBs and anti-throm-
botic therapy or the highest ACT values during CAS procedure. No patients developed CHS 
after CAS (  table 2  ).
  Multivariate analysis adjusted for age and vascular risk factors revealed that the presence 
of CMBs before CAS was an independent predictor of the appearance of new CMBs after 
CAS (odds ratio: 8.50, 95% confidence interval: 1.34–53.88;   table 3  ).
  Discussion 
  This study showed that (1) CMBs can develop rapidly after CAS, and (2) the presence of 
CMBs before CAS was an independent predictor of the appearance of new CMBs after CAS. 
A recent study suggested that the presence of CMBs and severe small vessel diseases are pre-
dictors of the rapid development of CMBs after acute ischemic stroke   [8]  . Hypertension is 
associated with CMBs in patients with stroke   [20]  . In our study, risk factors for stroke, in-
cluding hypertension, were not associated with the formation of new CMBs after CAS. Such 
risk factors may be important promoters of CMBs over a longer period but may not contrib-
ute to CMBs in the short term. The mechanism underlying the rapid formation of CMBs 
after CAS remains unknown. We speculate that hemodynamic changes caused by the CAS 13
Cerebrovasc Dis Extra 2012;2:9–16
 DOI:  10.1159/000337143 
  Published online: March 14, 2012 
EXTRA
  Kakumoto et al.: Rapid Formation of Cerebral Microbleeds after Carotid Artery Stenting 
www.karger.com/cee
  © 2012 S. Karger AG, Basel 
procedure affect damaged small cerebral vessels in patients with CMBs, and may disrupt the 
tight junction of cerebral blood vessels, resulting in CMBs.
  Several studies reported that low platelet counts were associated with symptomatic hem-
orrhagic transformation in acute ischemic stroke with atrial fibrillation   [21]   and a high risk 
of intracranial hemorrhage after intravenous recombinant tissue plasminogen activator 
Table 1.   Univariate factors for the development of new CMBs
N ew  CMBs
present (n   = 7) absent (n = 81) p value
Demographics
Age 74.087.9 71.587.1 0.37
Male sex 7 (100%) 69 (85%) 0.59
Symptomatic clinical presentation 4 (57%) 36 (44%) 0.70
Angiographic findings
Carotid stenosis (NASCET criteria), % 73.9815.0 72.5812.7 0.79
MRI findings
Presence of CMBs before CAS on GRE 4 (57%) 14 (17%) 0.03
Risk factors
Hypertension 4 (57%) 60 (74%) 0.38
Diabetes 3 (43%) 26 (32%) 0.68
Hyperlipidemia  3 (43%) 33 (41%) 1.00
Ischemic heart disease  4 (57%) 23 (28%) 0.19
Laboratory findings
Platelet count, !10,000 /ml 21.6812.7 20.485.9 0.81
Antithrombotic therapy 
Antiplatelet drug  
Dual therapy (aspirin + clopidogrel) 4 (57%) 53 (65%)
Triple therapy (aspirin + clopidogrel + cilostazol) 2 (27%) 20 (25%)
Antiplatelet drug + anticoagulation drug 
Dual antiplatelet drug + warfarin 0 5 (6%)
Triple antiplatelet drug + warfarin 1 (14%) 3 (4%) 0.55
The highest ACT values during CAS procedure, s 338.9855.0 340.8857.3 0.93
Val  ues are number (%), or mean 8 SD. p values are calculated using Student’s t test and the 2 test.
Table 2.   Demographics of patients with newly developed CMBs
Case No. Age 
years
Stenosis 
(NASCET 
criteria), %
CHS after 
CAS
CMBs before 
CAS, n
CMBs after 
CAS, n
New CMB 
hemisphere
1 68 56 no 1 3 ipsilateral
2 84 78 no 1 2 ipsilateral
3 77 80 no 0 1 ipsilateral
4 79 53 no 0 1 ipsilateral
5 73 70 no 0 1 ipsilateral
6 77 90 no 1 2 ipsilateral
7 60 90 no 1 2 ipsilateral14
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therapy for acute ischemic stroke   [22]  . There was no association between platelet counts and 
the development of new CMBs after CAS in our study.
  Dual antiplatelet therapy with clopidogrel and aspirin has been recommended as a stan-
dard therapy for the prevention of thrombotic events in patients undergoing CAS and intra-
cranial artery stenting   [23]  . All of the patients were treated with at least two antiplatelet 
drugs, aspirin and clopidogrel, and some patients were also administered cilostazol and/or 
warfarin. Since we did not find that the development of new CMBs after CAS was associated 
with antithrombotic therapy, strong antithrombotic therapy during the periprocedural pe-
riod may not be contraindicated by the presence of CMBs.
a
b
c
d
  Fig. 1.   A representative case de-
veloping new CMBs after CAS. 
T  2  *  -weighed GE MRI obtained 
in a 68-year-old man with symp-
tomatic left internal carotid ar-
tery stenosis (56%) before CAS 
( a ,   b  ) and the next day after CAS 
( c ,  d ). Arrowheads indicate base-
line CMBs. Arrows indicate new 
CMBs. 
OR 95% CI p value
Presence of CMBs before CAS 8.09 1.39–47.13 0.02
Age 1.08 0.96–1.21 0.20
Hypertension 0.26 0.04–1.80 0.17
Hyperlipidemia 1.31 0.22–7.63 0.77
Diabetes 2.46 0.32–19.10 0.39
Ischemic heart disease  3.10 0.49–19.48 0.23
O  R = odds ratio; CI = confidence interval.
Table 3.   Multiple logistic regres-
sion analysis of the development 
of new CMBs15
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    CHS is an uncommon but devastating complication following CAS and CEA, and is of-
ten fatal once cerebral hemorrhage occurs   [9–17]  . Before a CAS/CEA procedure, it is very 
important to evaluate the risks of cerebral hemorrhage in advance  .   CMBs may be a risk fac-
tor for ICH after CAS, and the development of new CMBs may also enhance this risk. Al-
though we had no patients with CHS after CAS in this series, we should pay special attention 
to the development of CHS in case of preexisting CMBs.
    Our study has some limitations. First, although we used defined MRI protocols for all 
patients before and after CAS, our study has a retrospective design and may have a potential 
risk for selection bias. It remains unknown whether CMBs are more frequent in patients with 
severe atherosclerotic changes in the carotid artery who undergo CAS than in those who do 
not require CAS. Second, this study is limited by its small sample size, and we could not com-
pletely evaluate several factors. Third, we used 1.5-T MRI, which is inferior to 3-T MRI 
for the detection of CMBs. The use of 3-T MRI might have allowed the detection of more 
CMBs   [24] .
    Our study suggests that new CMBs can occur rapidly after CAS. The presence of base-
line CMBs is associated with the development of new CMBs after CAS. A further prospective 
study with a larger sample size is intended to confirm these results.
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